Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04108195 · ClinicalTrials.gov registry record · Phase 1
A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 1
- Development phase
- 290
- Enrollment target
- 20
- Study locations
NCT04108195 is a Phase 1 study of Multiple Myeloma that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 290 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 9 states.
The verdict
NCT04108195, a Phase 1 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 290 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
Conditions Studied
Interventions
- DRUG Teclistamab
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Talquetamab
Study Locations (20)
Other
- Universitatsklinikum Freiburg - Freiburg im Breisgau
- Universitaetsklinikum Hamburg Eppendorf - Hamburg
- Universitaetsklinikum Heidelberg - Heidelberg
- Universitatsklinikum Wurzburg - Würzburg
- VU Medisch Centrum - Amsterdam
- LUMC - Leiden
- Hosp Clinic de Barcelona - Barcelona
- Inst. Cat. Doncologia-H Duran I Reynals - Barcelona
California
- City of Hope National Medical Center - Duarte
- City of Hope Orange County Lennar Foundation Cancer Center - Irvine
- University of California San Francisco - San Francisco
New York
- The Blavatnik Family Chelsea Medical Center at Mount Sinai - New York
- Mount Sinai Medical Center - New York
North Carolina
- Levine Cancer Institute - Charlotte
- Wake Forest Baptist Medical Center - Winston-Salem
Pennsylvania
- University of Pennsylvania - Philadelphia
Tennessee
- Vanderbilt Ingram Cancer Center - Nashville
Wisconsin
- Medical College Of Wisconsin - Milwaukee
Alberta
- Arthur J E Child Comprehensive Cancer Centre - Calgary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2020-02-21 |
| Est. Completion | 2027-04-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04108195
The ClinicalTrials.gov registry entry for NCT04108195 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (47% lower). The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Teclistamab is the first listed.
NCT04108195 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, California, New York.
Frequently Asked Questions
What is clinical trial NCT04108195 about?
NCT04108195 is a clinical study titled "A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma". The purpose of this study is to identify recommended Phase 2 doses (RP2Ds) for each treatment combination (between daratumumab plus talquetamab and teclistamab plus daratumumab with or without pomalidomide) and to characterize the safety of each RP2D for selected treatment combinations.
What is the current status of trial NCT04108195?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 290 participants. The study started on 2020-02-21. Estimated completion is 2027-04-07.
What conditions does trial NCT04108195 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT04108195?
The interventions under investigation include: Teclistamab (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Talquetamab (DRUG).
Who is sponsoring clinical trial NCT04108195?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04108195 being conducted?
This trial has 20 study locations across California, New York, North Carolina, Pennsylvania, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.